908 Devices Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; comparisons are with FY2020, not a standalone fourth quarter. 908 Devices develops and sells handheld and desktop mass spectrometry devices, consumables and services for field forensics and life-sciences applications.
Financial and operating highlights
| Metric | FY2021 | FY2020 |
|---|---|---|
| Total revenue | $42.2 million | $26.9 million |
| Product and service revenue | $41.1 million | $24.8 million |
| Device sales | $33.3 million | $21.3 million |
| Consumables and service revenue | $7.8 million | $3.5 million |
| Gross profit | $23.2 million | $14.9 million |
| Product and service gross margin | 55% | 55% |
| Operating loss | $(22.1) million | $(5.8) million |
| Net loss | $(22.2) million | $(12.8) million |
| Cash used in operating activities | $(29.1) million | Cash provided: $4.1 million |
| Cash and cash equivalents at year-end | $224.1 million | $159.2 million |
| Long-term debt at year-end | $15.0 million | $14.3 million, net of discount |
Revenue grew 57%. Product and service revenue increased 66%, led by handheld sales and higher consumables and service revenue. Device placements rose to 574 from 390; cumulative placements reached 1,935. Government customers generated $29.8 million of product and service revenue, pharmaceutical/biotechnology customers $11.3 million, and academia $0.1 million. One customer represented 43% of total revenue, versus 33% in FY2020.
Operating expenses increased to $45.3 million from $20.7 million, including R&D expense of $13.1 million and SG&A expense of $32.2 million. SG&A included a $1.7 million allowance for a doubtful Middle East customer receivable. Operating cash use reflected, among other items, increases in accounts receivable and inventory. The company raised $94.4 million net in a November 2021 public offering.
Liquidity included $252.9 million of current assets and $14.8 million of current liabilities at year-end. The $25 million revolving credit facility had $10 million available; borrowings bear interest at the greater of 0.5% above prime or 4.0%, and mature March 11, 2024. The company reported covenant compliance. The filing states cash and cash equivalents were expected to fund operating expenses, capital expenditures and debt service for at least 12 months.
Changes, outlook and risks
- Handheld product and service revenue rose to $29.2 million from $17.6 million; desktop revenue rose to $11.9 million from $7.1 million. Consumables and service revenue increased 124%, and its share of product and service revenue grew to 19% from 14%.
- License and contract revenue declined 49% to $1.1 million, primarily due to lower activity under a subcontract related to a U.S. government contract.
- Product and service gross margin held at 55%. Despite revenue growth, the operating loss widened, reflecting substantially higher SG&A and R&D investment. Net loss also increased.
- Management provided no specific forward revenue or earnings guidance in the supplied filing text. It expects continued losses and significant investment in sales, R&D, manufacturing capacity and product development; profitability timing is uncertain.
- Management reported ongoing COVID-19-related supply-chain and travel constraints. A $1.7 million receivable allowance was recorded for a Middle East customer; $1.7 million of the $3.0 million gross receivables from the relevant EMEA countries was more than 90 days past due.
- Key risks include customer and government-contract concentration, lengthy and unpredictable sales cycles, competition, execution of life-sciences and international expansion, dependence on some single-source components, supply constraints, and continued operating losses. Most manufacturing and corporate operations are concentrated at the Boston facility.
- No material legal proceedings were reported. The auditor gave an unqualified opinion on the financial statements; management concluded internal control over financial reporting was effective, but the auditor did not attest to it.
Important facts for investors to verify
- Whether the concentrated customer revenue and accounts receivable exposures have since diversified or been collected.
- Whether operating cash burn, receivables and inventory growth, and the $1.7 million doubtful-account allowance have improved.
- Whether consumables and service revenue continue to grow as the installed base expands, particularly for Rebel and ZipChip.
- Whether sales growth and production scale can improve margins enough to offset planned operating expense increases and move the company toward profitability.
- Current cash, revolving-credit availability, debt covenants and cash runway, compared with management’s stated expectation of at least 12 months of funding.
- Progress in reducing supply-chain and single-source supplier risks, and in broadening sales channels beyond government customers and distributors.